4001 Discovery Drive
Suite N321, UCB 027
About Muse Biotechnologies
Muse bio is transforming genome engineering by enabling, for the first time, high throughput massively-multiplexed CRISPR editing of proteins, pathways, and genomes. Through our powerful bioinformatics and novel molecular approach, ForgeCraft generates low-cost libraries of thousands of designer protein, pathway, or genome variants each with specifically defined, trackable mutations. This allows the impact of specific changes to be determined through rapid selection and high throughput screening allowing research timelines and costs to be reduced.
Founder and CSO: Ryan T Gill PhD
Founder, CTO and VP R&D: Tanya Lipscomb PhD
CEO: Kevin Ness, PhD
VP, Finance: Erik Warneke
VP, Corporate Development: Joey Money PhD
Please click here for Muse bio's technology.
6 articles with Muse Biotechnologies
Here’s a roundup of biopharma companies that have announced hiring trends since the beginning of the year.
The mysterious death of a biotech startup chief executive officer in late April projected the term biohacker into the forefront of the industry lexicon.
Gene-editing company Inscripta, formerly known as Muse Biotechnologies, will be able to expand its research capabilities and increase hiring after the company closed a Series C funding round of $55.5 million.